Cyanotech to Go Private via Reverse/Forward Stock Split, Forcing Out Small Shareholders
summarizeSummary
Cyanotech Corporation is executing a "going private" transaction through a 400-for-1 reverse stock split, followed by a 1-for-400 forward split, to reduce its shareholder count below 300 and deregister from the SEC, eliminating public reporting obligations.
check_boxKey Events
-
Going Private Transaction
Cyanotech will execute a 400-for-1 reverse stock split followed by a 1-for-400 forward split to reduce its shareholder count below 300, enabling it to cease being a public reporting company.
-
Deregistration from SEC
The company intends to terminate its SEC registration and suspend reporting obligations, citing significant cost savings, which were approximately $560,000 in 2025.
-
Forced Cash-Out for Small Shareholders
Stockholders owning fewer than 400 pre-split shares will be involuntarily cashed out at $0.47 per share, which is below the current market price of $0.499404.
-
Loss of Public Market Liquidity
The company's common stock will no longer be quoted on the OTCQB, with potential for reduced liquidity and transparency on lower OTC tiers.
auto_awesomeAnalysis
This SC 13E3 filing signals a critical shift for Cyanotech Corporation as it moves to terminate its public reporting status. The company aims to reduce administrative and compliance costs, which were approximately $560,000 in 2025, a substantial amount relative to its market capitalization. However, this transaction will significantly impact public shareholders. Those holding fewer than 400 shares will be involuntarily cashed out at $0.47 per share, which is below the current stock price of $0.499404. The deregistration will lead to a loss of transparency, reduced liquidity, and the cessation of quotation on the OTCQB, potentially moving to a lower, less regulated tier of the OTC Markets. While the company benefits from cost savings, the loss of public status and forced shareholder exit at a discount represents a material negative for investors.
At the time of this filing, CYAN was trading at $0.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.21 to $0.78. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.